Receive regular headline summaries whenever high-quality news is generated for this page. We'll never share your email address with others.
|4/20/2020||Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
... and McGill University to accelerate product development to enable faster uptake for patients—PoC studies planned later in 2020 Basel, April 20, 2020 — Novartis announced today that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the ...
|4/20/2020||Amblyotech, A Digital Therapeutics Company, Announces It Has Been Acquired by Novartis
Amblyotech Inc. is a clinical stage digital therapeutics company committed to the advancement of treatments and diagnostics for amblyopia (lazy eye) and other ocular disorders - Acquisition will advance this innovative therapeutic program intended to treat those who are afflicted with amblyopia and stereopsis vision disorders PHOENIX Amblyotech, a US-based ...
|4/20/2020||Novartis to acquire digital therapeutics maker Amblyotech
A large drugmaker is making a bet on a smaller firm that developed digital therapeutic technology for treating the condition commonly known as “lazy eye.” Basel, Switzerland-based Novartis said Monday that it had acquired Phoenix-based software startup Amblyotech , which is developing a digital treatment for amblyopia. Financial terms ...
|4/20/2020||Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye” Swiss Stock Exchange:NOVN||Globe Newswire|